Abstract:
The present invention relates to compounds, which inhibit dipeptidyl peptidase IV (DPP-IV) and are useful for the prevention or treatment of diabetes, especially type II diabetes, as well as hyperglycemia, metabolic syndrome , hyperinsulinemia, obesity, atherosclerosis, various immunomodulatory diseases, and other diseases.
Abstract:
The present invention relates to compounds, which inhibit dipeptidyl peptidase IV (DPP-IV) and are useful for the prevention or treatment of diabetes, especially type II, as well as hyperglycemia, metabolic syndrome, hyperinsulinemia, obesity, atherosclerosis, various immunomodulatory diseases, and other diseases.
Abstract:
The present invention relates to a compound of formula (I) and the pharmaceutically acceptable salts thereof wherein W is a bicyclic heterocyclic ring system. The compounds are alpha -1 adrenergic antagonists and are useful in the treatment of BPH; also disclosed are alpha -1 antagonist compositions and a method for antagonizing alpha -1 adrenoreceptors and treating BPH.
Abstract:
The present invention relates to a compound of formula (I) and the pharmaceutically acceptable salts thereof wherein W is a bicyclic heterocyclic ring system. The compounds are alpha -1 adrenergic antagonists and are useful in the treatment of BPH; also disclosed are alpha -1 antagonist compositions and a method for antagonizing alpha -1 adrenoreceptors and treating BPH.
Abstract:
The benzopyranopyrrole and benzopyranopyridine derivatives or a pharmaceutically acceptable salt or prodrug thereof have the formula I wherein: R1 and R2 are independently hydrogen, alkyl, alkenyl, alkynyl, alkoxyalkyl, alkoxy, alkoxycarbonyl, hydroxy, hydroxyalkyl, carboxy, carboxyalkyl, halogen, nitro, amino or aminoalkyl; A is methylene; n is 1 or 2; W is C2-10 alkylene; R3 is a group of formula 2; G is and G' are independently hydrogen, alkyl, alkenyl, alkynyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, hydroxy, hydroxyalkyl, carboxy, carboxyalkyl, halogen, alkylsulphonyl or aminoalkyl; Y and Y' are independently oxygen, nitrogen or sulphur provided that when Y is O or S then G is absent and when Y' is O or S then G' is absent; V and V' are independently nitrogen or methine and U is a ring that is fused to its adjacent ring and is: (a) an optionally substituted five member ring having five carbon atoms; (b) an optionally substituted five membered ring having four carbon atoms and one heteroatom being nitrogen, oxygen or sulphur; (c) an optionally substituted five membered ring having three carbon atoms and two heteroatoms independently being nitrogen, oxygen or sulphur; (d) an optionally substituted six membered ring having six carbon atoms; (e) an optionally substituted six membered ring having 5 carbon atoms and one heteroatom being nitrogen, oxygen or sulphur; (f) an optionally substituted 6 membered ring having 4 carbon atoms and two heteroatom independently being nitrogen, oxygen or sulphur or (g) an optionally substituted 6 membered ring having three carbon atoms and three heteroatoms independently being nitrogen, oxygen or sulphur. A pharmaceutical composition thereof is useful for antagonizing a-1-adrenoreceptors or for treating benign prostatic hyperplasia, bladder outlet obstruction, neurogenic bladder or uterine smooth muscle contraction in a mammal. Intermediates of formulae XV, XVI, XVII, XVIII, XIX, XX, XXI, XXII, XXIII, XXIV, XXV, XXVI, XXVII, XXVIII and XXIX are disclosed wherein: U, Y', G', R1 and R2 are as defined above; m is 2 to 10; X is halogen; R' is alkyl or arylalkyl; R is alkyl; Rz is alkyl and n is 0 or 1.
Abstract:
The present invention relates to a compound of formula (I) and the pharmaceutically acceptable salts thereof wherein W is a bicyclic heterocyclic ring system. The compounds are .alpha.-1 adrenergic antagonists and are useful in the treatment of BPH; also disclosed are .alpha.-1 antagonist compositions and a method for antagonizing .alpha.-1 adrenoreceptors and treating BPH.
Abstract:
Novel compounds which are selective dopamine agonists are useful for treating disorders characterized by abnormal dopamine levels, such as Parkinson's Disease, as well as cardiovascular disorders.
Abstract:
The present invention relates to compounds, which inhibit dipeptidyl peptidase IV (DPP-IV) and are useful for the prevention or treatment of diabetes, especially type II, as well as hyperglycemia, metabolic syndrome, hyperinsulinemia, obesity, atherosclerosis, various immunomodulatory diseases, and other diseases.
Abstract:
The invention relates to alpha-1 adrenergic antagonists, to alpha -1 antagonistic compositions and to a method for the antagonization of alpha-1 adrenoreceptors applicable for the treatment of benignant hyperplasia of the prostate gland (BPH). The compound and its pharmaceutically aceeptable salts have the general formula where W means bicyclic heterocyclic ring system. 54 claims